Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q3

4564.TEDINET S100Q6XE
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥700m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥335m2021-04-01 → 2021-12-31Cons.Net sales
Operating income−¥905m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥929m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥912m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥2.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥913m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥913m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.4bnat 2022-12-31Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥2.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥392mat 2022-12-31Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥2.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥978mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-4.742022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.522021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.732021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio68.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥290m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥79m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥172,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥536m
—segment totalrevenue2022-04-01 → 2022-12-31¥700m
—segment totalrevenue external2022-04-01 → 2022-12-31¥700m
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥172,000
—segment totalsegment profit2022-04-01 → 2022-12-31−¥615m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥282m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥337m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥8m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31−¥127m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥132,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.3bn
—segment totalrevenue2021-04-01 → 2021-12-31¥344m
—segment totalrevenue external2021-04-01 → 2021-12-31¥335m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥8m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 322
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member－
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member－
Number of shares held in own name treasury shares etcCurrentQuarterInstant－
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant－
Shareholding ratio treasury shares etcCurrentQuarterInstant－
Cash and depositsPrior1YearInstant1836906000JPY
Cash and depositsCurrentQuarterInstant977668000JPY
Accounts receivable tradePrior1YearInstant399747000JPY
Accounts receivable tradeCurrentQuarterInstant67499000JPY
Work in processPrior1YearInstant107941000JPY
Work in processCurrentQuarterInstant71325000JPY
Raw materials and suppliesPrior1YearInstant123101000JPY
Raw materials and suppliesCurrentQuarterInstant165880000JPY
Advance payments tradePrior1YearInstant19090000JPY
Advance payments tradeCurrentQuarterInstant12935000JPY
Other caPrior1YearInstant113764000JPY
Other caCurrentQuarterInstant59491000JPY
Current assetsPrior1YearInstant2600551000JPY
Current assetsCurrentQuarterInstant1354801000JPY
BuildingsPrior1YearInstant568281000JPY
BuildingsCurrentQuarterInstant548003000JPY
Accumulated depreciation and impairment loss buildingsPrior1YearInstant-568281000JPY
Accumulated depreciation and impairment loss buildingsCurrentQuarterInstant-548003000JPY
Buildings netPrior1YearInstant－JPY
Buildings netCurrentQuarterInstant－JPY
Machinery and equipmentPrior1YearInstant65503000JPY
Machinery and equipmentCurrentQuarterInstant63839000JPY
Accumulated depreciation and impairment loss machinery and equipmentPrior1YearInstant-65503000JPY
Accumulated depreciation and impairment loss machinery and equipmentCurrentQuarterInstant-63839000JPY
Machinery and equipment netPrior1YearInstant－JPY
Machinery and equipment netCurrentQuarterInstant－JPY
Tools furniture and fixturesPrior1YearInstant1161040000JPY
Tools furniture and fixturesCurrentQuarterInstant1156376000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesPrior1YearInstant-1161022000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesCurrentQuarterInstant-1156376000JPY
Tools furniture and fixtures netPrior1YearInstant17000JPY
Tools furniture and fixtures netCurrentQuarterInstant－JPY
Property plant and equipmentPrior1YearInstant17000JPY
Property plant and equipmentCurrentQuarterInstant－JPY
Guarantee deposits ioaPrior1YearInstant84630000JPY
Guarantee deposits ioaCurrentQuarterInstant89178000JPY
Investments and other assetsPrior1YearInstant84630000JPY
Investments and other assetsCurrentQuarterInstant89178000JPY
Noncurrent assetsPrior1YearInstant84648000JPY
Noncurrent assetsCurrentQuarterInstant89178000JPY
AssetsPrior1YearInstant2685199000JPY
AssetsCurrentQuarterInstant1443979000JPY
Accounts payable otherPrior1YearInstant422113000JPY
Accounts payable otherCurrentQuarterInstant213758000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass